---
title: "Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: Therapies after progression on PD-1 inhibitor and platinum"
description: "Formulary evidence on Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: Therapies after progression on PD-1 inhibitor and platinum. Topics: Amivantamab and hyaluronidase-lpuj: indication and limitation of use, Amivantamab and hyaluronidase-lpuj: date of accelerated approval, OrigAMI-4: population and prior therapy, OrigAMI-4: efficacy results, and 8 further topics. 12 evidence topics quoted from 12 sources."
canonical: "https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/product-information-and-disease-description/therapies-after-progression-on-pd-1-inhibitor-and-platinum"
published: "2026-11-15T21:46:22-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: Therapies after progression on PD-1 inhibitor and platinum

<a id="heading-2.2.2.1.5"></a>

## 2.2.2.1.5 Therapies After Progression on PD-1 Inhibitor and Platinum

<a id="topic-2.2.2.1.5-1"></a>

### Amivantamab and hyaluronidase-lpuj: indication and limitation of use

> “RYBREVANT FASPRO is indicated as a single agent for the treatment of adult patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) whose disease has progressed on or after platinum-based chemotherapy and an anti-PD-(L)1 antibody.”
> “Limitations of use: RYBREVANT FASPRO is not indicated as a treatment for patients with oropharyngeal squamous cell carcinoma (OPSCC) that is human papillomavirus (HPV)-associated (i.e., by p16 IHC).”
> “This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).”

Source: [Janssen RYBREVANT FASPRO prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761433s002lbl.pdf)

<a id="topic-2.2.2.1.5-2"></a>

### Amivantamab and hyaluronidase-lpuj: date of accelerated approval

> “On November 5, 2026, the Food and Drug Administration granted accelerated approval to amivantamab and hyaluronidase-lpuj (Rybrevant Faspro, Janssen Biotech, Inc.) for adults with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) whose disease has progressed on or after platinum-based chemotherapy and an anti-PD-(L)1 antibody.”
> “This application was granted priority review. Amivantamab and hyaluronidase-lpuj received breakthrough therapy designation.”

Source: [FDA (2026)](https://www.fda.gov/drugs/cancer-approvals/fda-grants-accelerated-approval-amivantamab-and-hyaluronidase-lpuj-recurrent-or-metastatic-head-and)

<a id="topic-2.2.2.1.5-3"></a>

### OrigAMI-4: population and prior therapy

> “The efficacy of RYBREVANT FASPRO as a single agent was evaluated in OrigAMI-4 (NCT06385080), a multicenter, open-label, multi-cohort clinical trial. The primary efficacy population included 102 patients with recurrent or metastatic HNSCC.”
> “Patients with HPV-associated OPSCC based on p16 testing results (only required for OPSCC), were excluded from the primary efficacy population.”
> “Eligible patients must have received previous treatment with platinum-based chemotherapy and an anti-PD-(L)1 antibody (in combination or as separate lines of therapy).”
> “52% had one prior line and 48% had two prior lines of systemic therapies.”

Source: [Janssen RYBREVANT FASPRO prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761433s002lbl.pdf)

<a id="topic-2.2.2.1.5-4"></a>

### OrigAMI-4: efficacy results

| Outcome | RYBREVANT FASPRO (N=102) |
| --- | --- |
| Overall response rate (95% CI) | “42% (32%, 52%)” |
| Complete response | “15%” |
| Partial response | “28%” |
| Duration of response, range (months) | “1.4+, 19.7+” |
| Patients with duration of response of 6 months or longer | “56%” |

Source: [Janssen RYBREVANT FASPRO prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761433s002lbl.pdf)

<a id="topic-2.2.2.1.5-5"></a>

### First approval in 10 years after prior platinum-based chemotherapy

> “This is the first approval in 10 years of a drug for patients with recurrent or metastatic HNSCC who had received prior platinum-based chemotherapy.”
> “Currently approved therapies are associated with an overall response rate of around 20% or less and poor outcomes.”

Source: [FDA press announcement (2026)](https://www.fda.gov/news-events/press-announcements/fda-grants-accelerated-approval-new-treatment-head-and-neck-squamous-cell-carcinoma)

<a id="topic-2.2.2.1.5-6"></a>

### Cetuximab monotherapy after platinum: indication and response

> “as a single-agent for the treatment of patients with recurrent or metastatic SCCHN for whom prior platinum-based therapy has failed.”
> “EMR 62202-016 was a single-arm, multicenter clinical trial in 103 patients with recurrent or metastatic SCCHN. All patients had documented disease progression within 30 days of a platinum-based chemotherapy regimen.”
> “The ORR was 13% (95% CI 7%, 21%). Median duration of response (DoR) was 5.8 months (range 1.2 to 5.8 months).”

Source: [ImClone ERBITUX prescribing information (2021)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125084s279lbl.pdf)

<a id="topic-2.2.2.1.5-7"></a>

### PD-1 inhibitors after platinum in disease not previously treated with a PD-1 inhibitor

> “Pembrolizumab or nivolumab should be offered to patients with platinum-refractory recurrent or metastatic HNSCC, regardless of CPS status (Type: Evidence based, benefits outweigh harms; Evidence quality: High; Strength of recommendation: Strong).”
> “The combination of anti–PD-1 inhibitors with other systemic treatments has been investigated in platinum-refractory disease; however, no combination has become standard of care to date.”

Source: [Yilmaz et al. (2023)](https://ascopubs.org/doi/10.1200/JCO.22.02328)

<a id="topic-2.2.2.1.5-8"></a>

### Pembrolizumab versus methotrexate, docetaxel, or cetuximab after platinum: overall survival

> “survival in the intention-to-treat population was 8·4 months (95% CI 6·4-9·4) with pembrolizumab and 6·9 months (5·9-8·0) with standard of care (hazard ratio 0·80, 0·65-0·98; nominal p=0·0161).”

Source: [Cohen et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/30509740/)

<a id="topic-2.2.2.1.5-9"></a>

### Next-line therapy after first-line pembrolizumab in KEYNOTE-048

> “The objective response rate on second-course pembrolizumab was 27.3% (3 of 11).”
> “PFS2 was similar after pembrolizumab and longer after pembrolizumab-chemotherapy on next-line taxanes and shorter after pembrolizumab and similar after pembrolizumab-chemotherapy on next-line nontaxanes.”

Source: [Harrington et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9902012/)

<a id="topic-2.2.2.1.5-10"></a>

### Salvage chemotherapy after anti-PD-(L)1 therapy: retrospective cohort

> “Retrospective cohort analysis of 63 R/M patients treated with SCT after antiPD-(L1)-based therapy between January 2015 and August 2022.”
> “Up to 71% received SCT as third line or beyond. ORR to SCT was 49% with higher rates in PD-L1 positive tumors, 71% vs. 18% (p=0.001), and cetuximab-containing regimens, 68% vs. 39% (p=0.026).”
> “OS and PFS were 9.3 months (95% CI, 6.5–12.3) and 4.1 months (95% CI, 3.0–5.8) respectively.”

Source: [Llop et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11625818/)

<a id="topic-2.2.2.1.5-11"></a>

### Cetuximab-based salvage chemotherapy after immune checkpoint inhibitors: real-world cohort

> “In recurrent/metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN) there is no established standard therapy after progression to immune checkpoint inhibitors (ICI).”
> “Among 80 patients, 96% and 100% received cetuximab-based first and second SCAI, respectively”
> “First SCAI: ORR of 59% (41/70; 31 partial and 10 complete responses)”
> “DoR of 9.4 months, and PFS and OS of 5.9 and 12.4 months, respectively”
> “grade 3–5 AEs, 38.7% (first SCAI) and 47% (second SCAI) with no toxic deaths.”

Source: [Cabezas-Camarero et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12827138/)

<a id="topic-2.2.2.1.5-12"></a>

### Range of response and survival with conventional salvage regimens

> “Conventional salvage regimens (taxanes, methotrexate, cetuximab) yield response rates of 21–69% but with short median PFS (2.9–5.5 months) and OS (6.3–13.3 months)”
> “As a result, there is no clear standard of care choice in second-line treatment”

Source: [Abraham et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12691436/)

Additional sources: [Reverdy et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37562096/); [Wakasaki et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/31128940/)

## Related pages
- [Ficerafusp alfa (BCA101): First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab.md)
- [Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: Terms and abbreviations](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/terms-and-abbreviations.md)
- [Ficerafusp alfa (BCA101): First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/executive-summary) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/executive-summary.md)
- [Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: Product information and disease description](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/product-information-and-disease-description.md)
- [Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: Clinical evidence](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/clinical-evidence.md)
- [Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: Economic information and modeling report](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/economics) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/economics.md)
- [Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: References](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/references) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/references.md)
